• Financing Provided by Investor Syndicate including Apple Tree Partners, NEA,
BioStar Ventures, and Windham Venture Partners
• Company to Invest in Multi-center CE Mark Trial and IDE Approval of its Revolutionary
Integrated Imaging and Ablation Platform for the Treatment of Atrial Fibrillation
Sunnyvale, CA, July 29, 2016 – VytronUS, Inc. ("VytronUS"), a privately held medical device
company developing novel technologies for the treatment of cardiac arrhythmias, announced
today that it has secured $49 million in Series C equity financing. The current syndicate of
investors enthusiastically supported this financing. Proceeds will be used for technology
refinements and clinical trials of VytronUS’s proprietary Low-Intensity Collimated Ultrasound
(LICU™) Cardiac Mapping & Ablation System to treat atrial fibrillation and other arrhythmias.
"This financing is the culmination of the excellent progress the company has made over the last
two years. We have developed a potentially game-changing technology platform, underscored
by our successful clinical results to date,” said John Pavlidis, CEO of VytronUS. “We greatly
appreciate the commitment of our distinguished syndicate of investors and will use this
infusion of capital to execute the multi-center EU and US clinical validation of our technology,"
VytronUS is developing a next-generation integrated imaging and ablation platform for cardiac
electrophysiologists. Harnessing the capability of ultrasound energy, the VytronUS system
creates a high resolution image of the interior of the heart for procedure planning and allows
the physician to simply draw a desired treatment pattern on the image at the workstation.
"The VytronUS system offers a potentially winning combination for AF and VT ablation: facile
rendering of the 3D left atrial or ventricular anatomy, continuous transmural lesions without
tissue contact, and importantly, the flexibility for operator-defined lesion paths with tissue
thickness information," said Vivek Reddy, MD, Helmsley Trust Professor of Medicine, Mount
Sinai Hospital, New York, NY.
David McIntyre, Partner at Apple Tree Partners and VytronUS director, commented: “Despite
significant limitations associated with currently available technologies, catheter ablation
continues to be one of the fastest growing markets in the medical device sector. We are
enthusiastic to continue our investment in VytronUS’s technology platform and outstanding
team to support the company in the clinical validation phase.”
Justin Klein, MD, JD, Partner at NEA and VytronUS director, added: “We have been long-term
supporters of VytronUS because we believe the company’s revolutionary technology has the
potential to help millions of people all over the world. With this latest investment, the company
is very well positioned for success in multi-center clinical trials.”
About Apple Tree Partners
Apple Tree Partners ("ATP") is a $1.67 billion venture capital firm dedicated to building
healthcare businesses. ATP takes the long view as a matter of principle and for value
creation. ATP is actively investing in medical devices, pharmaceuticals, biotech, and healthcare
About New Enterprise Associates
New Enterprise Associates (“NEA”) is a leading venture capital firm focused on helping
entrepreneurs build transformational businesses across multiple stages, sectors, and
geographies. With over $13 billion in committed capital, the firm invests in information
technology, healthcare, and energy technology companies at all stages in a company’s lifecycle,
from seed stage through IPO. NEA’s long track record of successful investing includes more than
200 portfolio company IPOs and more than 320 acquisitions.
About BioStar Ventures
BioStar Ventures is a venture capital partnership to enhance and monetize the experience and
knowledge of physician thought leaders in medical care and technology with successful and
knowledgeable health care business leaders, and experienced venture capitalists to invest
primarily in early stage medical device companies. BioStar Ventures’ unique marriage of worldrenowned clinicians with experienced venture capitalists and business leaders allows BioStar
Ventures to capture unique deal flow and leverage decades of scientific knowledge, clinical
expertise, and patient care delivery experience to benefit its investment process.
About Windham Venture Partners
Founded in 2006, Windham is a New York City-based venture capital firm focused on
healthcare, with a particular emphasis on medical technology (devices and diagnostics) and
digital health (the intersection of healthcare and information technology). Windham seeks to
invest in and partner with companies that are commercializing game-changing technologies to
serve unmet needs, improve the lives of large numbers of patients, and yield robust returns for
VytronUS, Inc. was formed to harness the imaging and therapeutic capabilities of ultrasound
energy to treat cardiac arrhythmias, starting with atrial fibrillation. The company has developed
a catheter-based ablation platform based on Low-Intensity Collimated Ultrasound (LICU™).
LICU allows for precise non-contact energy delivery and is capable of quickly producing highresolution maps of cardiac anatomy. The VytronUS system is designed to allow physicians to
treat complex arrhythmias with unmatched visualization, precision, flexibility, and automation.
John Pavlidis, President & CEO